Restoration of coronary microvascular function by OGA overexpression in a high-fat diet with low-dose streptozotocin-induced type 2 diabetic mice
Name:
cabrera-et-al-2023.pdf
Size:
1.448Mb
Format:
PDF
Description:
Final Published Version
Affiliation
Department of Physiology, University of ArizonaIssue Date
2023-05-15
Metadata
Show full item recordPublisher
SAGE Publications LtdCitation
Cabrera JT, Si R, Tsuji-Hosokawa A, et al. Restoration of coronary microvascular function by OGA overexpression in a high-fat diet with low-dose streptozotocin-induced type 2 diabetic mice. Diabetes and Vascular Disease Research. 2023;20(3). doi:10.1177/14791641231173630Rights
© The Author(s) 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Sustained hyperglycemia results in excess protein O-GlcNAcylation, leading to vascular complications in diabetes. This study aims to investigate the role of O-GlcNAcylation in the progression of coronary microvascular disease (CMD) in inducible type 2 diabetic (T2D) mice generated by a high-fat diet with a single injection of low-dose streptozotocin. Inducible T2D mice exhibited an increase in protein O-GlcNAcylation in cardiac endothelial cells (CECs) and decreases in coronary flow velocity reserve (CFVR, an indicator of coronary microvascular function) and capillary density accompanied by increased endothelial apoptosis in the heart. Endothelial-specific O-GlcNAcase (OGA) overexpression significantly lowered protein O-GlcNAcylation in CECs, increased CFVR and capillary density, and decreased endothelial apoptosis in T2D mice. OGA overexpression also improved cardiac contractility in T2D mice. OGA gene transduction augmented angiogenic capacity in high-glucose treated CECs. PCR array analysis revealed that seven out of 92 genes show significant differences among control, T2D, and T2D + OGA mice, and Sp1 might be a great target for future study, the level of which was significantly increased by OGA in T2D mice. Our data suggest that reducing protein O-GlcNAcylation in CECs has a beneficial effect on coronary microvascular function, and OGA is a promising therapeutic target for CMD in diabetic patients. © The Author(s) 2023.Note
Open access articleISSN
1479-1641PubMed ID
37186669Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.1177/14791641231173630
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The Author(s) 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
Related articles
- Overexpression of p53 due to excess protein O-GlcNAcylation is associated with coronary microvascular disease in type 2 diabetes.
- Authors: Si R, Zhang Q, Tsuji-Hosokawa A, Watanabe M, Willson C, Lai N, Wang J, Dai A, Scott BT, Dillmann WH, Yuan JX, Makino A
- Issue date: 2020 May 1
- O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
- Authors: Makino A, Dai A, Han Y, Youssef KD, Wang W, Donthamsetty R, Scott BT, Wang H, Dillmann WH
- Issue date: 2015 Nov 1
- eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes.
- Authors: Gao L, Ramirez FJ, Cabrera JTO, Varghese MV, Watanabe M, Tsuji-Hosokawa A, Zheng Q, Yang M, Razan MR, Kempf CL, Camp SM, Wang J, Garcia JGN, Makino A
- Issue date: 2024 Sep
- HuR/Cx40 downregulation causes coronary microvascular dysfunction in type 2 diabetes.
- Authors: Si R, Cabrera JTO, Tsuji-Hosokawa A, Guo R, Watanabe M, Gao L, Lee YS, Moon JS, Scott BT, Wang J, Ashton AW, Rao JN, Wang JY, Yuan JX, Makino A
- Issue date: 2021 Nov 8
- Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy.
- Authors: Fricovsky ES, Suarez J, Ihm SH, Scott BT, Suarez-Ramirez JA, Banerjee I, Torres-Gonzalez M, Wang H, Ellrott I, Maya-Ramos L, Villarreal F, Dillmann WH
- Issue date: 2012 Oct 1